Competitive Pressure Mounts for Viking Therapeutics in Weight-Loss Drug Race

Viking Therapeutics' oral obesity drug VK2735 trails rival's Phase 2 data. The stock is down 147% from analyst targets amid Q4 losses and insider selling.

The landscape for oral weight-loss medications is becoming increasingly competitive, with new clinical data from a rival firm posing a significant challenge to Viking Therapeutics. Structure Therapeutics has released Phase 2 results for its GLP-1 candidate, Aleniglipron, demonstrating a placebo-adjusted weight reduction of 16.3 percent over a 44-week period. This performance places considerable pressure on Viking's own oral contender, VK2735, which achieved a 14.7 percent weight reduction in its Phase 2 trials.

Financial Performance and Strategic Updates

While Viking's pipeline shows activity, its recent financial report disappointed market observers. For the fourth quarter of 2025, the company reported a loss per share of $1.38, falling substantially short of the analyst consensus estimate of $0.89. Viking's shares recently closed at $35.53. This price sits approximately 147 percent below the average analyst price target of $87.80. The majority of covering analysts maintain a "Moderate Buy" rating on the equity.

On the strategic front, Viking presented pipeline updates at the Leerink Global Healthcare Conference on March 10. The company's lead obesity drug, VK2735, is now advancing through Phase 3 studies. Separately, its NASH program, VK2809, has successfully completed a Phase 2b study.

Shifts in Ownership and Market Sentiment

Recent trading activity reveals notable moves by major shareholders. During the third quarter, Kintayl Capital LP decreased its stake by 22.7 percent, selling 29,416 shares. Over the past 90 days, company insiders have collectively disposed of roughly 364,731 shares, valued at $12.05 million. Despite these sales, institutional investors and hedge funds continue to hold a dominant 76.03 percent of outstanding shares, while insiders retain a 4.10 percent stake.

Market skepticism remains palpable, as evidenced by a significant short interest position of nearly 22 percent. The coming Phase 3 data for VK2735 is now viewed as a critical benchmark. Its ability to match or exceed the efficacy demonstrated by Structure's Aleniglipron will likely be the decisive factor in any potential re-rating of Viking's stock.